Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CF101 Phase 3 in Dry Eye Disease
NCT01235234Phase 3Completed
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Jul 2011
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of piclidenoson in dry eye disease (DED) (3 arms), sponsored by Can-Fite BioPharma Ltd. Primary endpoints: Number of Subjects Who Achieved Complete Clearing of Corneal Staining (Total Corneal FS Score = 0) at 24 weeks and Number of Subjects With Adverse Events at 24 weeks. Started Jul 2011; status: completed.
02
Drugs
piclidenoson
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT01235234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01235234.